Echinomycin (NSC 526417) in recurrent and metastatic squamous cell carcinoma of the cervix
- 1 March 1992
- journal article
- clinical trial
- Published by Springer Nature in Investigational New Drugs
- Vol. 10 (1) , 25-26
- https://doi.org/10.1007/bf01275474
Abstract
Nineteen evaluable patients with recurrent or metastatic squamous cell carcinoma of the uterine cervix were treated with 1,500μg/m2 of echinomycin every 4 weeks. No patient had received prior chemotherapy. There was one partial response (5% response, 95% confidence interval for response of 0% to 26%). The major toxicity was nausea and vomiting which was moderate to severe in six patients. Myelosuppression was not observed. Echinomycin, in this dose and schedule displays no major activity in chemotherapy-naive patients with advanced squamous-cell carcinoma of the cervix.Keywords
This publication has 7 references indexed in Scilit:
- Echinomycin (NSC 526417) in Squamous-Cell Carcinoma of the CervixAmerican Journal of Clinical Oncology, 1990
- PHASE-I STUDY OF ECHINOMYCIN ADMINISTERED ON AN INTERMITTENT BOLUS SCHEDULE1985
- Echinomycin: The first bifunctional intercalating agent in clinical trialsInvestigational New Drugs, 1985
- Activity of two phase I drugs N-methylformamide (NSC-3051) and Echinomycin (NSC-526417) against fresh surgical explants of human tumors in the 6-day subrenal capsule (SRC) assayInvestigational New Drugs, 1983
- cis-Dichlorodiammineplatinum(II) in the treatment of gynecologic malignancies: phase II trials by the Gynecologic Oncology Group.1979